Methodology: IHC

Clinical Significance:
CD200, a cell surface antigen expressed in a variety of benign and neoplastic tissues, is thought to promote immune evasion by tumors. CD200 evaluation can help distinguish chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL, usually CD200-positive) from mantle cell lymphoma (almost always CD200-negative).

Subcellular Localization: Membranous and cytoplasmic

Organ: Blood/Bone Marrow, Lymph Node / Spleen

Disease State: Angioimmunoblastic T Cell Lymphoma, Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL), Plasma Cell Myeloma/Neoplasm

CPT Code(s): 88342 or 88341

Turnaround Time: Within 1-2 business days of receipt

Schedule: Monday - Friday

Specimen Requirements:
• Formalin-fixed, paraffin-embedded (FFPE) tissue block or cell block - OR -
• 1 unstained slide for each test requested plus 3-4 additional unstained slides cut at 4µm